Clinical Trial Update: Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated the additive effect of twice-daily brinzolamide/brimonidine combination as adjunctive therapy to travoprost in normal tension glaucoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Normal Tension Glaucoma

Drugs mentioned

• Travoprost (Travoprost (isomer-free))
• brinzolamide 1%/brimonidine 0.2% (brinzolamide and brimonidine combination)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glaucoma | Phase 4 | Status: COMPLETED | Results posted: 2019-02-25